The markets sold off, but IPOs continued to get done, with four deals raising $1.5 billion. High-growth Brazilian payments company StoneCo (STNE) even priced its $1.1 billion offering above the range, and then flew up 30%. Cooler company...read more
Gamida Cell, a Phase 3 biotech developing stem cell therapies for hematologic malignancies, raised $50 million by offering an upsized 6.25 million shares at $8, below the range of $13 to $15. Gamida offered 75% more shares than expected to keep the deal size at...read more
Five IPOs and one SPAC are scheduled to raise $1.7 billion in the week ahead. The price cuts and postponements this past week showed that IPO buyers are in firm control. StoneCo (STNE) is aiming to raise $1.05 billion in the year's ninth...read more
Gamida Cell, a Phase 3 biotech developing therapies for hematologic malignancies, announced terms for its IPO on Wednesday. The Jerusalem, Israel-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15....read more
US IPO Weekly Recap: Billion-dollar StoneCo IPO pops 30% despite market turmoil
The markets sold off, but IPOs continued to get done, with four deals raising $1.5 billion. High-growth Brazilian payments company StoneCo (STNE) even priced its $1.1 billion offering above the range, and then flew up 30%. Cooler company...read more
Stem cell biotech Gamida Cell prices $50 million IPO below the range at $8
Gamida Cell, a Phase 3 biotech developing stem cell therapies for hematologic malignancies, raised $50 million by offering an upsized 6.25 million shares at $8, below the range of $13 to $15. Gamida offered 75% more shares than expected to keep the deal size at...read more
US IPO Week Ahead: Yeti coolers and a billion-dollar payments company lead 5-IPO week
Five IPOs and one SPAC are scheduled to raise $1.7 billion in the week ahead. The price cuts and postponements this past week showed that IPO buyers are in firm control. StoneCo (STNE) is aiming to raise $1.05 billion in the year's ninth...read more
Israel-based biotech Gamida Cell sets terms for $50 million US IPO
Gamida Cell, a Phase 3 biotech developing therapies for hematologic malignancies, announced terms for its IPO on Wednesday. The Jerusalem, Israel-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15....read more